What are the recommended management strategies for hot flushes in women, including non‑pharmacologic measures and pharmacologic therapies?

Management of Hot Flushes

For women with moderate to severe hot flushes, menopausal hormone therapy (MHT) remains the most effective treatment and should be first-line unless contraindicated; when MHT cannot be used, SSRIs/SNRIs (particularly paroxetine or venlafaxine), gabapentin, or pregabalin are recommended as effective alternatives. 1

Algorithmic Approach to Treatment

Step 1: Assess Severity and Contraindications

For mild or less bothersome hot flushes:

• Start with non-pharmacologic measures: lower ambient temperature, dress in layers, avoid alcohol and spicy foods, address obesity and stress 1
• These lifestyle modifications should be attempted first before escalating to medications

For moderate to severe hot flushes:

• Proceed to pharmacologic therapy based on contraindications to hormonal treatment

Step 2: Pharmacologic Treatment Selection

If NO contraindications to hormones (First-Line):

Menopausal Hormone Therapy (MHT) is superior to all non-hormonal agents 1

• Women WITHOUT a uterus: Use estrogen alone (transdermal preferred due to fewer adverse effects) 1
• Women WITH a uterus: Use combined estrogen-progestogen therapy 1
  • Alternative: CEE/bazedoxifene combination (where available) 1
• Duration: Revisit the decision to continue MHT at least annually, targeting shortest duration consistent with treatment goals 1

Special population - Young women with premature ovarian insufficiency or early menopause:

• Continue MHT until the age of natural menopause (approximately age 51), then reassess 1

If MHT is contraindicated or patient refuses (Second-Line):

Recommended non-hormonal prescription therapies in order of preference 1:

1. SSRIs/SNRIs (most preferred non-hormonal option):

   • Paroxetine 7.5-25 mg (only FDA-approved SSRI for hot flushes) 2
   • Venlafaxine 75-150 mg (preferred by two-thirds of patients over gabapentin in head-to-head trials) 1
   • Desvenlafaxine 100-150 mg
   • Citalopram 10-20 mg or Escitalopram 10-20 mg 1, 3
   • These reduce hot flash frequency by approximately 60-70% 1

2. Gabapentin 900-2400 mg/day (or 300-1200 mg based on individual tolerance):

   • Particularly effective for nighttime hot flushes when given as single bedtime dose 1
   • Reduces hot flash scores by 65-71% 1
   • Caution: Daytime use may cause intolerable lethargy 1

3. Pregabalin 150-300 mg/day (75-150 mg twice daily):

   • Similar efficacy to gabapentin 1

Step 3: If First Non-Hormonal Therapy Fails

If inadequate response or intolerance to SSRIs/SNRIs, gabapentin, or pregabalin:

• Trial of clonidine (transdermal patches preferred over tablets for stable blood levels) 1
• Note: Clonidine is less effective than the above agents and has more side effects 1

Critical Contraindications and Drug Interactions

For SSRIs/SNRIs:

• Avoid in patients with prior neuroleptic syndrome, serotonin syndrome, or concurrent MAO inhibitor use 1
• Use caution in bipolar disease, uncontrolled seizures, hepatic/renal insufficiency, hyponatremia 1
• Critical for breast cancer patients on tamoxifen: Avoid medications that interact with CYP2D6 (particularly paroxetine and fluoxetine) as they reduce tamoxifen efficacy 3

For Gabapentin/Pregabalin:

• May increase suicidal thoughts, cause drowsiness/dizziness, impair balance and coordination 1
• Pregabalin may additionally impair memory and concentration 1

Non-Pharmacologic Alternatives with Evidence

Interventions with demonstrated efficacy 3, 4:

• Hypnosis: Significant reduction in hot flush scores 3, 4
• Acupuncture: Small but significant effect on hot flush-related daily interference 4
• Cognitive behavioral therapy (CBT): Modest effect at post-treatment 4

Ineffective interventions to avoid 3:

• Homeopathy, vitamin E, alanine, omega-3, red clover, black cohosh, primrose oil, physical activity alone

Common Pitfalls

1. Underestimating MHT efficacy: Limited head-to-head trials suggest standard-dose MHT is more effective than all non-hormonal agents 1
2. Inappropriate discontinuation approach: Use shared decision-making for gradual taper versus abrupt discontinuation 1
3. Forgetting annual reassessment: MHT continuation should be revisited yearly 1
4. Using phytoestrogens in breast cancer patients: All phytoestrogens are contraindicated in this population 3
5. Ignoring drug interactions: Particularly CYP2D6 inhibitors in tamoxifen users 3